Black Rock Inc. Galectin Therapeutics Inc Transaction History

Black Rock Inc.

$4.35 Trillion
Q2 2024

A detailed history of Black Rock Inc. transactions in Galectin Therapeutics Inc stock. As of the latest transaction made, Black Rock Inc. holds 1,563,783 shares of GALT stock, worth $3.89 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,563,783

Previous 712,638 119.44%

Holding current value

$3.89 Million

Previous $1.7 Million 107.52%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$2.13 - $4.2 $1.81 Million - $3.57 Million	851,145 Added 119.44%	1,563,783 $3.53 Million
Q1 2024 May 10, 2024	SELL	$1.6 - $2.44 $4,340 - $6,619	-2,713 Reduced 0.38%	712,638 $1.7 Million
Q4 2023 Feb 13, 2024	SELL	$1.6 - $2.18 $16,916 - $23,049	-10,573 Reduced 1.46%	715,351 $1.19 Million
Q3 2023 Nov 13, 2023	SELL	$1.38 - $1.97 $61,161 - $87,310	-44,320 Reduced 5.75%	725,924 $1.39 Million
Q2 2023 Aug 11, 2023	SELL	$1.32 - $2.08 $3,787 - $5,967	-2,869 Reduced 0.37%	770,244 $1.11 Million
Q1 2023 May 12, 2023	BUY	$1.1 - $2.4 $2,233 - $4,872	2,030 Added 0.26%	773,113 $1.62 Million
Q4 2022 Feb 13, 2023	BUY	$1.03 - $1.66 $1,858 - $2,994	1,804 Added 0.23%	771,083 $871,000
Q3 2022 Nov 14, 2022	SELL	$1.31 - $2.48 $8,241 - $15,601	-6,291 Reduced 0.81%	769,279 $1.25 Million
Q2 2022 Aug 12, 2022	SELL	$1.19 - $1.74 $25,167 - $36,799	-21,149 Reduced 2.65%	775,570 $1.02 Million
Q1 2022 May 12, 2022	BUY	$1.61 - $2.31 $5,947 - $8,533	3,694 Added 0.47%	796,719 $1.28 Million
Q4 2021 Feb 10, 2022	BUY	$2.07 - $3.8 $11,267 - $20,683	5,443 Added 0.69%	793,025 $1.64 Million
Q3 2021 Nov 09, 2021	SELL	$2.59 - $4.15 $16,451 - $26,360	-6,352 Reduced 0.8%	787,582 $3.06 Million
Q2 2021 Aug 11, 2021	BUY	$2.07 - $5.1 $1.64 Million - $4.05 Million	793,934 New	793,934 $2.54 Million

Others Institutions Holding GALT

# of Institutions

Shares Held

9.36M

Call Options Held

982K

Put Options Held

2.7K

View Full List

About GALECTIN THERAPEUTICS INC

Ticker GALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,426,000
Market Cap $148M
Description
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial f...

More about GALT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.

Account